“One of the challenges I have seen companies face in developing drugs for emerging markets is creating a solid pipeline of promising products that directly address the unique needs of patients, and that are priced appropriately for the health systems in those markets. Naia’s founding team has the deep worldwide relationships with academia and industry required to identify relevant innovative drug development opportunities, and to effectively bring these new medicines to their respective regions. Naia is building a diverse portfolio of late-stage preclinical and clinical assets that address critical regional and global unmet medical needs.”
Dr Omar Haffar PhD
Naia Board of Directors
Omar Haffar PhD is a cell biologist with 28 years of experience in the biotechnology industry.
He is currently the founder, president and chief executive officer of Eos Biosciences Inc, a nanomedicines company based in Los Angeles. He began his career at Genentech, Inc and then worked at Bristol-Myers Squibb. He was co-founder and vice president of anti-infectives at Cytokine Networks and subsequently was founder and president of International Therapeutics, Inc. He served as managing director at Global Solutions for Infectious Diseases and was the principal founder, president and chief executive officer of Presidio Pharmaceuticals Inc. Dr Haffar serves on the Board of Directors of Eos Biosciences and Presidio Pharmaceuticals.
Dr Haffar received his B.S. in biology from the American University of Beirut in Lebanon and his MS in biology from the University of Oregon. He completed his PhD in physiology-anatomy at the University of California, Berkeley.